Phase I Dose-Escalation Trial of CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) T-Cells for the Treatment of Relapsed or Refractory B-Cell Lymphomas and Chronic Lymphocytic Leukemia
- Resource Type
- Abstract
- Source
- In
Blood 5 November 2020 136 Supplement 1:19-20 - Subject
- Language
- ISSN
- 0006-4971